Background:
Patients who survive severe brain injury may develop chronic disorders of consciousness
(DoC). Treating these patients to improve recovery is extremely challenging because of scarce
and inefficient therapeutical options. Among pharmacological treatments, apomorphine, a
potent direct dopamine agonist, has exhibited promising behavioral effects, but its true
efficacy and its mechanism remains unknown. This randomized controlled study aims to verify
the effects of apomorphine subcutaneous infusion in patients with disorders of consciousness
and investigate the neural networks targeted by this treatment.
Methods/design:
The double-blind randomized controlled trial will include 48 patients: 24 patients will be
randomly assigned to the apomorphine and 24 to the placebo group. Investigators and the
patients will be unaware of the nature of the treatment rendered.
Primary outcome will be determined as behavioral response to treatment as measured by changes
of diagnosis using the Coma Recovery Scale - Revised (CRS-R), while secondary outcome
measures will include the Nociception Coma Scale - Revised (NCS-R), Disability Rating Scale
(DRS), Wessex Head Injury Matrix (WHIM), circadian rhythm using actimetry,
electroencephalography (EEG), positron emission tomography (PET) and functional magnetic
resonance imaging (fMRI). The Glasgow Outcome Scale - Extended (GOS-E) and a phone-adapted
version of the CRS-R will be used for long-term follow-up.
Statistical analyses will focus on the detection of changes induced by apomorphine treatment
at the individual level (comparing data before and after treatment) and at the group level
(comparing responders with non-responders). Response to treatment will be measured at four
different levels: 1. behavioral response (CRS-R, NCS-R, DRS, WHIM, GOS-E, phone CRS-R), 2.
brain metabolism (PET), 3. network connectivity (resting-state fMRI, clinical EEG and
high-density EEG) and 4. Circadian rhythm changes (actimetry, body temperature, 24h-EEG).
Discussion:
Apomorphine is a promising and safe strategy for the treatment of DoC but efficacy, profile
of the responding population and underlying mechanism remain to be determined. This trial
will provide unprecedented data that will allow to investigate the response to apomorphine
using multimodal methods and shed new light on the brain networks targeted by this drug in
terms of behavioral response, functional connectivity and metabolism.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Liege
Collaborators:
Centre Hospitalier Neurologique William Lennox (Belgium) Centre Hospitalier Universitaire Vaudois (Switzerland) Radboud University Medical Centre (the Netherlands) VITHAS Valencia (Spain)